Dendorfer A, Dominiak P
Institut of Pharmacology, Medical University of Lübeck, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Mar;351(3):274-81. doi: 10.1007/BF00233247.
The rat pheochromocytoma cell line PC12, which is a widely used model for analyzing stimulus-secretion coupling, was investigated for the effects of kinins on catecholamine release. Subtypes of kinin receptors were characterized using the B1 agonist desArg9-bradykinin, the B2 agonist bradykinin and the B2 antagonists [Thi5,8, D-Phe7]-bradykinin, D-Arg-[Hyp3, D-Tic7, Oic8]-bradykinin (HOE 890307) and D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin (HOE 140). The effectiveness of acute and chronic exposure to angiotensin I converting enzyme inhibitors as well as pretreatment of the cells with bacterial lipopolysaccharides in modulating B1 or B2 receptor systems was also tested. Bradykinin stimulated noradrenaline release from PC12 cells at low concentrations (EC50 = 1 nM), maximally inducing a release of 43.7% of the cellular content within 15 min. In comparison with acetylcholine and K(+)-induced depolarization, bradykinin was the most effective stimulus. DesArg9-bradykinin was only effective at very high concentrations (> 30 microM). Like in other neuronal cells, the B2-specific partial antagonist [Thi5,8, D-Phe7]-bradykinin acted as a low-affinity agonist without any antagonistic effects. The B2 antagonists HOE 890307 and HOE 140 exerted no agonistic effects and concentration-dependently inhibited bradykinin-induced noradrenaline release, showing competitive antagonism with Ki values of 1.38 nM and 0.66 nM, respectively. Only at the highest concentration used (1 microM), HOE 140 did depress the maximal response to bradykinin. HOE 890307 also abolished the effects of desArg9-bradykinin and [Thi5,8, D-Phe7]-bradykinin.(ABSTRACT TRUNCATED AT 250 WORDS)
大鼠嗜铬细胞瘤细胞系PC12是一种广泛用于分析刺激-分泌偶联的模型,本研究探讨了激肽对儿茶酚胺释放的影响。使用B1激动剂去精氨酸9-缓激肽、B2激动剂缓激肽以及B2拮抗剂[噻吩5,8,D-苯丙氨酸7]-缓激肽、D-精氨酸-[Hyp3,D-噻唑啉7,Oic8]-缓激肽(HOE 890307)和D-精氨酸-[Hyp3,噻吩5,D-噻唑啉7,Oic8]-缓激肽(HOE 140)对激肽受体亚型进行了鉴定。还测试了急性和慢性暴露于血管紧张素I转换酶抑制剂以及用细菌脂多糖预处理细胞对调节B1或B2受体系统的有效性。缓激肽在低浓度(EC50 = 1 nM)时刺激PC12细胞释放去甲肾上腺素,在15分钟内最大诱导释放细胞内含量的43.7%。与乙酰胆碱和钾离子诱导的去极化相比,缓激肽是最有效的刺激物。去精氨酸9-缓激肽仅在非常高的浓度(> 30 microM)时有效。与其他神经元细胞一样,B2特异性部分拮抗剂[噻吩5,8,D-苯丙氨酸7]-缓激肽作为低亲和力激动剂,没有任何拮抗作用。B2拮抗剂HOE 890307和HOE 140没有激动作用,并浓度依赖性地抑制缓激肽诱导的去甲肾上腺素释放,表现出竞争性拮抗作用,Ki值分别为1.38 nM和0.66 nM。仅在使用的最高浓度(1 microM)时,HOE 140确实降低了对缓激肽的最大反应。HOE 890307也消除了去精氨酸9-缓激肽和[噻吩5,8,D-苯丙氨酸7]-缓激肽的作用。(摘要截短至250字)